FINWIRES · TerminalLIVE
FINWIRES

PYC Therapeutics' Blinding Eye Disease Treatment Candidate Gets Orphan Drug Designation in Europe

By

-- PYC Therapeutics (ASX:PYC) said its VP-001 drug candidate for blinding eye disease Retinitis Pigmentosa type 11 received orphan drug designation from the European Medicines Agency, according to a Monday filing with the Australian bourse.

The benefits of the designation include scientific advice and other assistance from the European regulator, lower regulatory fees for the drug candidate's review, and 10 years of exclusivity in the European market once approved.

VP-001 previously obtained orphan drug designation and fast track status from the US Food and Drug Administration, PYC Therapeutics said.

Related Articles

International

Ifo: German Export Morale Inches Up in April

German exporters turned slightly optimistic in April, while the overall sector moved neither forward nor backward due to geopolitical uncertainty, the ifo Institute said Monday.The ifo export expectations indicator increased to 0.1 point in April, from -0.7 points in March, as positive expectations roughly offset negative ones.Across the board, the export outlook for the automotive industry, electronics sector, and furniture manufacturers declined but remained generally positive. Expectations for shipments of food and beverages increased "significantly," while energy-intensive businesses forecasted lower exports.

$^SXXP
Mining & Metals

Big Banc Split to Complete Class A Share Split

Big Banc Split (BNK.TO) intends to complete a stock split of its Class A shares, citing strong performance of the shares, the fund said late on Friday.Class A shareholders of record at the close of business on May 1 will receive 20 additional Class A shares for every 100 Class A shares held.At completion of the share split, the Class A shares are expected to begin trading on an ex-split basis at the opening of trading on May 4.The preferred shares of the fund will not be affected and are expected to have downside protection from a decline in the value of the fund's portfolio of about 60%.Class A unitholders will continue to receive regular monthly non-cumulative cash distributions initially in the amount of $0.12 per Class A share, or $1.44 per year, following the Share Split. As a result, the total dollar amount of distributions to be paid to the holders of Class A shares is expected to increase by about 20%.The share split is subject to the approval of the Toronto Stock Exchange.

$BNK.TO
Japan

WTI, Brent Crude Futures Rise Pre-Bell as US, Iran Fail to Engage in Face-to-Face Talks in Pakistan